criver.com (CRL): Net earnings per share for the last 12 months

Charles River Laboratories International, Inc. (CRL) - corporate logo

Charles River Laboratories (CRL) is recognized as the gold standard in preclinical testing, maintaining impeccable trust among institutional investors. The company's trailing 12-month net profit per share demonstrates capital management dynamics, where 0.90 reflects the metric's baseline. However, stringent bioethical standards and lengthy accreditation processes create high barriers to entry, while shrinking biotech startup budgets and a primate shortage are weighing on margins.

CRL Charles River Corp Net earnings per share for the last four quarters (07/04/2022 - 11/14/2026)

Analytical breakdowns for Charles River Lab (CRL)

- current quotes and average value forecast:
Price Chart Charles River Laboratories International, Inc.|CRL - Analyst Median Target
- stock exchange capitalization data:
Market Valuation Charles River Laboratories|CRL - Aggregate Business Value
- balance sheet net asset value indicators:
Net Assets per Single Share Charles River|CRL - Book Valuation of Business|Market Capitalization to Book Value Ratio criver.com|CRL - Cumulative Company Assets
- business debt structure and liquidity details:
Total Debt to Capital Charles River Laboratories|CRL - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Charles River Corp|CRL - Company Aggregate Debts|Debt to Book Capitalization Ratio Charles River Corp|CRL - Company Long-Term Loans and Borrowings|Company Short-Term Debt Charles River|Quick Ratio criver.com
- earnings and multiples data:
CRL - Company Net Income|Expected Profit Charles River Laboratories|CRL - Business Payback Period|Projected Price to Earnings Charles River Lab|CRL - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Charles River Corp|CRL - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Charles River|CRL - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months criver.com|CRL - Earnings per share growth in current year|Earnings growth forecast for next year Charles River Laboratories
- total revenue and sales volume data:
CRL - Company Total Revenue|Company Projected Revenue Charles River|CRL - Market Capitalization-to-Revenue Ratio|Forward Price-to-Revenue Multiple Charles River Corp
Analysis of all company metrics:CRL - Charles River
Manufactured products of Charles River Laboratories International, Inc.

Net income per share over 12 months measures the actual equity income of Charles River Laboratories (CRL), stripping the final financial result of the influence of the total number of securities. By analyzing the annual net income per share trend, an investor can see the effectiveness of the expense structure adaptation under James Foster's leadership during a period of stabilizing demand in the biotech sector.

Competing companies

IQV - Earnings per share for the last twelve months|Labcorp Holdings - Earnings per share for the last four quarters|Medpace Corp (MEDP) - Earnings per share for the last twelve months|ICLR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months evotec.com|FTRE (fortrea.com) - Earnings per share for the last four quarters|Earnings per share for the last twelve months Lifecore (LFCR)|Net earnings per share for the last four quarters OmniAb Inc.|Net earnings per share (EPS TTM) NOTV (Inotiv Corporation)|Net earnings per share (EPS TTM) Avid Bioservices, Inc. CDMO|Catalent, Inc - Net earnings per share (EPS TTM)|nighthawkbio.com (SCPX) - Net earnings per share for the last 12 months